Cargando…

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients

BACKGROUND: The importance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in hepatocellular carcinoma (HCC) has been studied extensively in Japan, where hepatitis C virus is the predominant aetiology of HCC. The clinical profiles of HCC regarding the state of AFP and DCP in a hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yang-Xun, Sun, Xu-Qi, Hu, Zi-Li, Xie, Wa, Nie, Ke-Xin, Fang, Ai-Ping, Zhang, Ying-Yao, Fu, Yi-Zhen, Chen, Jin-Bin, Wang, Jun-Cheng, Wang, Xin, Zhang, Yao-Jun, Hu, Dan-Dan, Chen, Min-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243598/
https://www.ncbi.nlm.nih.gov/pubmed/34235104
http://dx.doi.org/10.2147/JHC.S316223
_version_ 1783715779640819712
author Pan, Yang-Xun
Sun, Xu-Qi
Hu, Zi-Li
Xie, Wa
Nie, Ke-Xin
Fang, Ai-Ping
Zhang, Ying-Yao
Fu, Yi-Zhen
Chen, Jin-Bin
Wang, Jun-Cheng
Wang, Xin
Zhang, Yao-Jun
Hu, Dan-Dan
Chen, Min-Shan
author_facet Pan, Yang-Xun
Sun, Xu-Qi
Hu, Zi-Li
Xie, Wa
Nie, Ke-Xin
Fang, Ai-Ping
Zhang, Ying-Yao
Fu, Yi-Zhen
Chen, Jin-Bin
Wang, Jun-Cheng
Wang, Xin
Zhang, Yao-Jun
Hu, Dan-Dan
Chen, Min-Shan
author_sort Pan, Yang-Xun
collection PubMed
description BACKGROUND: The importance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in hepatocellular carcinoma (HCC) has been studied extensively in Japan, where hepatitis C virus is the predominant aetiology of HCC. The clinical profiles of HCC regarding the state of AFP and DCP in a hepatitis B virus epidemic area have not been comprehensively investigated, and the value of these tumour markers in evaluating the response to treatment and the detection of recurrence has yet to be determined. PATIENTS AND METHODS: A total of 4792 patients treated in our centre were continuously analysed regarding accessible AFP and DCP data pre- and posttreatment. Baseline characteristics were summarized, and comparisons of progression-free survival (PFS) and overall survival (OS) rates were made independently. The prognostic significance of each factor was tested with the Cox proportional hazards model. Patients who had AFP and DCP data pretreatment, pre- and posttreatment, and those who were continuously monitored more than twice were analysed separately. RESULTS: A total of 2600 patients (53.4%) were positive for AFP and DCP; 362 (7.6%) and 1211 (25.3%) patients were AFP- or DCP-positive, respectively, and 619 patients (12.9%) were negative for both AFP and DCP. Patients in the AFP single-positive or double-negative groups had the best OS (P<0.001). Patients with less than 50% responses in AFP and DCP after treatments suffered from worse prognostic survival (P<0.001). In the multivariate analysis, elevated AFP and DCP were identified as independent prognostic factors of PFS and OS. In addition, different tumour markers were related to different clinical and pathological traits. CONCLUSION: The present study comprehensively explored the clinical value of classical tumour markers for HCC using the “point-to-line” method. Positivity of pretreatment AFP and DCP or less than 50% treatment response rates exhibited more aggressive HCC, resulting in poor PFS and OS in HCC patients.
format Online
Article
Text
id pubmed-8243598
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82435982021-07-06 Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients Pan, Yang-Xun Sun, Xu-Qi Hu, Zi-Li Xie, Wa Nie, Ke-Xin Fang, Ai-Ping Zhang, Ying-Yao Fu, Yi-Zhen Chen, Jin-Bin Wang, Jun-Cheng Wang, Xin Zhang, Yao-Jun Hu, Dan-Dan Chen, Min-Shan J Hepatocell Carcinoma Original Research BACKGROUND: The importance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in hepatocellular carcinoma (HCC) has been studied extensively in Japan, where hepatitis C virus is the predominant aetiology of HCC. The clinical profiles of HCC regarding the state of AFP and DCP in a hepatitis B virus epidemic area have not been comprehensively investigated, and the value of these tumour markers in evaluating the response to treatment and the detection of recurrence has yet to be determined. PATIENTS AND METHODS: A total of 4792 patients treated in our centre were continuously analysed regarding accessible AFP and DCP data pre- and posttreatment. Baseline characteristics were summarized, and comparisons of progression-free survival (PFS) and overall survival (OS) rates were made independently. The prognostic significance of each factor was tested with the Cox proportional hazards model. Patients who had AFP and DCP data pretreatment, pre- and posttreatment, and those who were continuously monitored more than twice were analysed separately. RESULTS: A total of 2600 patients (53.4%) were positive for AFP and DCP; 362 (7.6%) and 1211 (25.3%) patients were AFP- or DCP-positive, respectively, and 619 patients (12.9%) were negative for both AFP and DCP. Patients in the AFP single-positive or double-negative groups had the best OS (P<0.001). Patients with less than 50% responses in AFP and DCP after treatments suffered from worse prognostic survival (P<0.001). In the multivariate analysis, elevated AFP and DCP were identified as independent prognostic factors of PFS and OS. In addition, different tumour markers were related to different clinical and pathological traits. CONCLUSION: The present study comprehensively explored the clinical value of classical tumour markers for HCC using the “point-to-line” method. Positivity of pretreatment AFP and DCP or less than 50% treatment response rates exhibited more aggressive HCC, resulting in poor PFS and OS in HCC patients. Dove 2021-06-25 /pmc/articles/PMC8243598/ /pubmed/34235104 http://dx.doi.org/10.2147/JHC.S316223 Text en © 2021 Pan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pan, Yang-Xun
Sun, Xu-Qi
Hu, Zi-Li
Xie, Wa
Nie, Ke-Xin
Fang, Ai-Ping
Zhang, Ying-Yao
Fu, Yi-Zhen
Chen, Jin-Bin
Wang, Jun-Cheng
Wang, Xin
Zhang, Yao-Jun
Hu, Dan-Dan
Chen, Min-Shan
Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title_full Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title_fullStr Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title_full_unstemmed Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title_short Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
title_sort prognostic values of alpha-fetoprotein and des-gamma-carboxyprothrombin in hepatocellular carcinoma in china: an analysis of 4792 patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243598/
https://www.ncbi.nlm.nih.gov/pubmed/34235104
http://dx.doi.org/10.2147/JHC.S316223
work_keys_str_mv AT panyangxun prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT sunxuqi prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT huzili prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT xiewa prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT niekexin prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT fangaiping prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT zhangyingyao prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT fuyizhen prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT chenjinbin prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT wangjuncheng prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT wangxin prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT zhangyaojun prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT hudandan prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients
AT chenminshan prognosticvaluesofalphafetoproteinanddesgammacarboxyprothrombininhepatocellularcarcinomainchinaananalysisof4792patients